Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018.
<h4>Background</h4>Visceral obesity (VATob) increases the risk for many diseases. Central obesity has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, the aim was to evaluate the association between VATob and prescription...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0318413 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864095248482304 |
|---|---|
| author | Maximino Acevedo-Fernández Renata Ochoa Precoma Leonardo M Porchia Victor M Posadas Enrique Torres-Rasgado M Elba Gonzalez-Mejia Esther López-Bayghen |
| author_facet | Maximino Acevedo-Fernández Renata Ochoa Precoma Leonardo M Porchia Victor M Posadas Enrique Torres-Rasgado M Elba Gonzalez-Mejia Esther López-Bayghen |
| author_sort | Maximino Acevedo-Fernández |
| collection | DOAJ |
| description | <h4>Background</h4>Visceral obesity (VATob) increases the risk for many diseases. Central obesity has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, the aim was to evaluate the association between VATob and prescription use.<h4>Methods</h4>Data was collected from the NHANES dataset (2011-2018). Visceral adipose tissue was measured using dual x-ray absorptiometry, and VATob was defined as ≥100 cm2. Prescription use was collected from the RXQ_RX files and classified according to Vademecum. Association between VATob and prescription use was determined with logistic regression and reported as odds ratios (ORs) with 95% confidence intervals (95%CIs).<h4>Results</h4>10,952 participants (weighted: 121,090,702) were included, in which 41.8% were VATob and 52.0% of them had ≥1 prescription. Overall, VATob demonstrated an augmented rate of prescription use when compared to non-VATob (52.0% versus 36.7%, p<0.001), specifically with metabolic (4.5-fold increase), cardiovascular (3.9-fold increase), gastrointestinal (2.5-fold increase), and hematopoietic agents (2.3-fold increase). This was associated with increased the risk for overall prescription use (ORoverall = 1.9, 95%CI: 1.7-2.1, p<0.001). Similar results were observed with metabolic and cardiovascular agents. However, when stratified by BMI, normal weight participants (ORmetabolic = 10.4; 95%CI: 6.5-16.6 & ORcardiovascular = 7.0; 95%CI: 4.4-11.1, p<0.001) had a greater risk than the overweight (ORmetabolic = 4.1; 95%CI: 3.0-5.6 & ORcardiovascular = 3.4; 95%CI: 2.5-4.7, p<0.001) or obese participants (ORmetabolic = 3.5; 95%CI: 2.3-5.3 & ORcardiovascular = 3.5; 95%CI: 2.5-4.9, p<0.001).<h4>Conclusion</h4>VATob is associated with augmented prescription use, particularly with cardiovascular and metabolic agents. This association was higher for normal weight participants. |
| format | Article |
| id | doaj-art-83d4d171f9684be9ba2d6b4367d4c75b |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-83d4d171f9684be9ba2d6b4367d4c75b2025-02-09T05:30:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01202e031841310.1371/journal.pone.0318413Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018.Maximino Acevedo-FernándezRenata Ochoa PrecomaLeonardo M PorchiaVictor M PosadasEnrique Torres-RasgadoM Elba Gonzalez-MejiaEsther López-Bayghen<h4>Background</h4>Visceral obesity (VATob) increases the risk for many diseases. Central obesity has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, the aim was to evaluate the association between VATob and prescription use.<h4>Methods</h4>Data was collected from the NHANES dataset (2011-2018). Visceral adipose tissue was measured using dual x-ray absorptiometry, and VATob was defined as ≥100 cm2. Prescription use was collected from the RXQ_RX files and classified according to Vademecum. Association between VATob and prescription use was determined with logistic regression and reported as odds ratios (ORs) with 95% confidence intervals (95%CIs).<h4>Results</h4>10,952 participants (weighted: 121,090,702) were included, in which 41.8% were VATob and 52.0% of them had ≥1 prescription. Overall, VATob demonstrated an augmented rate of prescription use when compared to non-VATob (52.0% versus 36.7%, p<0.001), specifically with metabolic (4.5-fold increase), cardiovascular (3.9-fold increase), gastrointestinal (2.5-fold increase), and hematopoietic agents (2.3-fold increase). This was associated with increased the risk for overall prescription use (ORoverall = 1.9, 95%CI: 1.7-2.1, p<0.001). Similar results were observed with metabolic and cardiovascular agents. However, when stratified by BMI, normal weight participants (ORmetabolic = 10.4; 95%CI: 6.5-16.6 & ORcardiovascular = 7.0; 95%CI: 4.4-11.1, p<0.001) had a greater risk than the overweight (ORmetabolic = 4.1; 95%CI: 3.0-5.6 & ORcardiovascular = 3.4; 95%CI: 2.5-4.7, p<0.001) or obese participants (ORmetabolic = 3.5; 95%CI: 2.3-5.3 & ORcardiovascular = 3.5; 95%CI: 2.5-4.9, p<0.001).<h4>Conclusion</h4>VATob is associated with augmented prescription use, particularly with cardiovascular and metabolic agents. This association was higher for normal weight participants.https://doi.org/10.1371/journal.pone.0318413 |
| spellingShingle | Maximino Acevedo-Fernández Renata Ochoa Precoma Leonardo M Porchia Victor M Posadas Enrique Torres-Rasgado M Elba Gonzalez-Mejia Esther López-Bayghen Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018. PLoS ONE |
| title | Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018. |
| title_full | Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018. |
| title_fullStr | Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018. |
| title_full_unstemmed | Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018. |
| title_short | Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018. |
| title_sort | visceral obesity augments prescription use an analysis of the cross sectional study of nhanes 2011 2018 |
| url | https://doi.org/10.1371/journal.pone.0318413 |
| work_keys_str_mv | AT maximinoacevedofernandez visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 AT renataochoaprecoma visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 AT leonardomporchia visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 AT victormposadas visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 AT enriquetorresrasgado visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 AT melbagonzalezmejia visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 AT estherlopezbayghen visceralobesityaugmentsprescriptionuseananalysisofthecrosssectionalstudyofnhanes20112018 |